Hepatitis C. Issues in Children

Gastroenterology Clinics of North America

Volumn 44, Issue 4, 2015, Pages 901-909

  Lee, Christine K ^a   Jonas, Maureen M ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Children; Direct acting antiviral; Hepatitis C; Pegylated interferon; Perinatal transmission; Ribavirin

Indexed keywords

DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; INTERFERON; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ANTIVIRUS AGENT;

ABSENCE OF SIDE EFFECTS; ACUTE HEPATITIS C; CHILD; CHRONIC HEPATITIS C; CLINICAL EXAMINATION; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG FEVER; DRUG INDUCED HEADACHE; GASTROINTESTINAL SYMPTOM; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MEDICAL HISTORY; NEUTROPENIA; NONHUMAN; PATIENT ASSESSMENT; POLYMERASE CHAIN REACTION; RETINOPATHY; REVIEW; SIDE EFFECT; TERATOGENICITY; TREATMENT RESPONSE; VERTICAL TRANSMISSION; VIRUS INHIBITION; VIRUS TRANSMISSION; WEIGHT REDUCTION; ACUTE DISEASE; COMBINATION DRUG THERAPY; COMPLICATION; DRUG ADMINISTRATION; GENETICS; GENOTYPE; HEPACIVIRUS; PREVENTION AND CONTROL; TRANSMISSION;

ACUTE DISEASE; ANTIVIRAL AGENTS; CHILD; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL;

EID: 84947612228     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2015.07.011     Document Type: Review

References (42)

1. World Health Organization Hepatitis C- global prevalence (update). Wkly Epidemiol Rec 2000, 75:18-19.
2. Gower E., Estes C., Blach S., et al. Global epidemiology and genotype distribution of the hepatitis C virus. J Hepatol 2014, 61(1):45-57.
3. Ditah I., Ditah F., Devaki P., et al. The changing epidemiology of hepatitis C virus infection in the United States: national health and nutrition examination survey 2001 through 2010. J Hepatol 2014, 60(4):691-698.
4. Armstrong G., Wasley A., Simard E., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
5. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States 1988-1994. N Engl J Med 1999, 341:556-562.
6. Yeung L.T., Kim S.M., Roberts E.A. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001, 34:223-229.
7. Jonas M.M., Baron M.J., Bresee J.S., et al. Clinical and virologic features of hepatitis C virus infection associated with intravenous immunoglobulin. Pediatrics 1996, 98:211.
8. Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus. Hepatology 2015, AASLD/ HCV Guidelines Panel, in press.
9. Jhaveri R. Diagnosis and management of hepatitis C virus-infected children. Pediatr Infect Dis J 2011, 30(11):983-985.
10. Minola E., Prati D., Suter F., et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 2002, 99:4588-4591.
11. Casiraghi M.A., De Paschale M., Romano L., et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 2004, 39:90-96.
12. Matsuoka S., Tatara K., Hayabuchi Y., et al. Serologic, virologic and histologic characteristics of chronic phase hepatitis C virus disease in children infected by transfusion. Pediatrics 1994, 94:919-922.
13. Vogt M., Lang T., Frosner G., et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999, 341:866-870.
14. Tovo P.A., Pembrey L.J., Newell M.L. Persistence rate and progression of vertically acquired hepatitis C infection. European Paediatric Hepatitis C infection. J Infect Dis 2000, 181:419-424.
15. Mohan P., Colvin C., Glymph C., et al. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr 2007, 150:168-174.
16. Matsuoka S., Tatara K., Hayabuchi Y., et al. Post-transfusion chronic hepatitis C in children. J Paediatr Child Health 1994, 30:544-546.
17. European Paediatric Hepatitis C Virus Network Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 2005, 41:45-51.
18. Guido M., Bortolotti F., Leandro G., et al. Fibrosis in chronic hepatitis c acquired in infancy: is it only a matter of time?. Am J Gastroenterol 2003, 98:660-663.
19. Birnbaum A.H., Shneider B.L., Moy L. Hepatitis C in children. N Engl J Med 2000, 342:290-291.
20. Badizadegan K., Jonas M.M., Ott M.J., et al. Histopathology of the liver in children with chronic hepatitis c viral infection. Hepatology 1998, 28:1416-1423.
21. Goodman Z.D., Makhlouf H.R., Liu L., et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008, 47:836-843.
22. Delgado-Borrego A., Healey D., Negre B., et al. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2010, 51(2):191-197.
23. El-Kamary S.S., Serwint J.R., Joffe A., et al. Prevalence of hepatitis C virus infection in urban children. J Pediatr 2003, 143:54-59.
24. Delgado-Borrego A., Smith L., Jonas M.M., et al. Expected and actual case ascertainment and treatment rates for children infected with hepatitis C in Florida and the United States: epidemiologic evidence from statewide and nationwide surveys. J Pediatr 2012, 161:915-921.
25. Raynes-Greenow C., Polis S., Elliott E., et al. Childhood hepatitis C virus infection: an Australian national surveillance study of incident cases over five years. J Paediatr Child Health 2015, 10.1111/jpc.12904.
26. Mack C.L., Gonzalez-Peralta R.P., Gupta N., et al. NASPGHAN practice guidelines. Diagnosis and management of hepatitis C infection in infants, children and adolescents. J Pediatr Gastroenterol Nutr 2012, 54:838-855.
27. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
28. Conte D., Fraquelli M., Prati D., et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000, 31:751-755.
29. Guido M., Rugge M., Jara P., et al. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology 1998, 115:1525-1529.
30. Gonzalez-Peralta R.P., Langham M.R., Andres J.M., et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2009, 48:630-635.
31. Druyts E., Thorlund K., Wu P., et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis 2013, 56:961-967.
32. Schwarz K.B., Gonzalez-Peralta R.P., Murray K.F., et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011, 140(2):450-458.
33. Wirth S., Ribes-Koninckx C., Calzado M.A., et al. High sustained virologic response rates in children with chronic hepatitis c receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010, 52:501-507.
34. Domagalski K., Pawlowska M., Tretyn A., et al. Impact of IL-28B polymorphism on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4. Eur J Clin Microbiol Infect Dis 2013, 32:745-754.
35. Shaker O.G., Nassar Y.H., Nour Z.A., et al. Single-nucleotide polymorphisms of IL-10 and IL-28B as predictors of the response of IFN therapy in HCV genotype 4-infected children. J Pediatr Gastroenterol Nutr 2013, 57:155-160.
36. Jonas M.M., Balistreri W., Gonzalez-Peralta R.P., et al. Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial. Hepatology 2012, 56:523-531.
37. Narkewicz M.R., Rosenthal P., Schwarz K.B., et al. Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon. J Pediatr Gastroenterol Nutr 2010, 51:183-186.
38. Benova L., Mohamoud Y.A., Calvert C., et al. Vertical transmission of hepatitis C virus; systematic review and meta-analysis. Clin Infect Dis 2014, 59:765-773.
39. Resti M., Azzari C., Lega L., et al. Mother-to-infant transmission of hepatitis C virus. Acta Paediatr 1995, 84:251-255.
40. Mast E.E., Hwang L.Y., Seto D.S., et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005, 192:1880-1889.
41. American Academy of Pediatrics Hepatitis C. Red Book; 2015 report of committee on infectious diseases 2015, 423-430. American Academy of Pediatrics, Elk Grover Village (IL). 30th edition. L.K. Pickering (Ed.).
42. Vegnente A., Iorio R., Saviano A., et al. Lack of intrafamilial transmission of hepatitis C virus in family members of children with chronic hepatitis C infection. Pediatr Infect Dis J 1994, 13:886-889.